Additional Charges Against Valeant Pharma (VRX) or Former Execs Cannot Be Ruled Out - Wells Fargo's Maris
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Wells Fargo analyst David Maris weighed in on Valeant Pharma (NYSE: VRX) after today's DOJ press conference. Maris said based on the comments additional charges against Valeant or former Valeant executives cannot be ruled out,
Maris commented, "Earlier in the day, a Valeant spokesperson indicated that given the charges brought today involved fraud against Valeant and in their view it is difficult to be a victim and guilty at the same time, that today's news was somehow good news for Valeant, or at least not as bad as it could have been. Given Mr. Bharara's statement, we believe it is premature for investors to believe that charges against the company and/or former executives are not in their future. On the contrary, we believe based on today's statements by Mr. Bharara, additional charges against Valeant or former Valeant executives cannot be ruled out, given this well-resourced and ongoing investigation."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Valeant Pharma (VRX) Talks to Sell Salix to Takeda for $10B Have Broken Down - DJ
- Exclusive: U.S. standards council to investigate New Oriental after Reuters report
- Skyline Medical (SKLN) Appoints New CEO, Board Member
Create E-mail Alert Related CategoriesAnalyst Comments, Litigation, Rumors, Trader Talk
Related EntitiesWells Fargo, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!